William Blair Investment Management LLC reduced its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,576,135 shares of the biopharmaceutical company’s stock after selling 27,307 shares during the period. William Blair Investment Management LLC owned about 1.27% of Cytokinetics worth $103,883,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB boosted its holdings in Cytokinetics by 63.8% in the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 157,700 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in Cytokinetics during the 3rd quarter worth about $1,549,000. Great Lakes Advisors LLC purchased a new position in shares of Cytokinetics during the 2nd quarter valued at about $1,960,000. Siren L.L.C. purchased a new position in shares of Cytokinetics during the 1st quarter valued at about $40,466,000. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of Cytokinetics by 93.0% in the 2nd quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company’s stock valued at $10,073,000 after buying an additional 56,971 shares during the period.
Insiders Place Their Bets
In other Cytokinetics news, EVP Fady Malik sold 3,500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $75.46, for a total transaction of $264,110.00. Following the transaction, the executive vice president owned 153,902 shares in the company, valued at approximately $11,613,444.92. This represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the completion of the sale, the director directly owned 10,784 shares in the company, valued at approximately $770,840.32. The trade was a 31.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 178,426 shares of company stock worth $12,208,290. Company insiders own 2.60% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Analysis on CYTK
Cytokinetics Stock Performance
Shares of Cytokinetics stock opened at $56.13 on Monday. The firm has a 50-day simple moving average of $64.11 and a two-hundred day simple moving average of $69.78. The company has a market cap of $7.82 billion, a P/E ratio of -9.29 and a beta of 0.45. Cytokinetics, Incorporated has a fifty-two week low of $53.55 and a fifty-two week high of $88.31.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The business had revenue of $47.56 million for the quarter, compared to analyst estimates of $41.88 million. During the same quarter last year, the business earned ($2.55) earnings per share. Cytokinetics’s revenue was up 2356.5% on a year-over-year basis. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.85 EPS for the current year.
Cytokinetics Profile
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Further Reading
- Five stocks we like better than Cytokinetics
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
